Press ReleasesChanelle McCoy Granted Approval For Significant Ultra Pure Synthetic CBD Phase...

Chanelle McCoy Granted Approval For Significant Ultra Pure Synthetic CBD Phase III Efficacy Clinical Trial



  • UK company Chanelle McCoy Health granted Ethics Approval to commence Phase III Efficacy Clinical Trial for the treatment of Sleep Disturbance CMH-CBD-001 using their Ultra Pure Synthetic Cannabinoid (CBD) formulation with pharmaceutical grade FDA registered raw material.
  • After already investing greatly in Phase I Safety and Toxicity Pre-Clinical Trials to support their product, this is the next step in achieving an Over-The-Counter (OTC) pharmacy only medicine license.
  • The company can begin recruiting participants for this Efficacy Clinical Trial, registering as a Schedule 3 CBD product for the Australian market, allowing CBD to be sold in pharmacy without a prescription, to improve sleep. 
  • Upon successful completion of this clinical trial, the company will start launching the product on the Australian Market with ambitions to move into the UK market. There are currently no CBD medicine products sold in pharmacy without a prescription on any global market.

R&D Pharmaceutical company, Chanelle McCoy Health, founded by Lady Chanelle McCoy and Caroline Glynn, are pleased to announce they have received Ethics Approval from Bellberry Human Research Ethics Committee in Australia. Today’s major milestone will enable the company to begin recruiting for this pivotal clinical trial. 

The results of the clinical trial should give key data on the efficacy of Ultra Pure Synthetic CBD in relation to sleep disturbance and improved sleep.

This CBD formulation (CMH-CBD-001) which received Ethics Approval in Australia has the highest quality of pharmaceutical grade raw material being FDA Registered with a Drug Master File.

The company has already successfully completed Phase I Safety and Toxicity Pre-Clinical Trials which revealed their Ultra Pure Synthetic CBD was well tolerated and there was no sign of adverse behaviour in the dose ranges proposed in the efficacy trial.

Successful completion of the Phase III Efficacy Clinical Trial, coupled with their substantial existing scientific data, will support the company’s registration as a pharmacy only medicine product with Australian health authorities, Therapeutic Goods Administration (TGA). This enables pharmacists to supply Chanelle McCoy Health’s Ultra Pure CBD (CMH-CBD-001) product to Australian patients without a prescription for the treatment of sleep disturbance and improve sleep. 

CMH-CBD-001 product contains Ultra Pure Synthetic CBD, which is NOT derived from the cannabis plant. This ensures NO pollutants, toxins, terpenes, heavy metals, pesticides, insecticides and no other harmful natural cannabinoid compounds including THC that can occur naturally in the cannabis plant. 

Also, there is no concern about crop failure, no reliance on weather or soil conditions which affects yield of plant grown source, minimal water usage and is more sustainable and environmentally friendly. No intra batch variability meaning each batch is the exact same, this may differ in plant sources due to different harvest conditions.  Synthetic CBD is scalable to produce large batch sizes which reduces cost and risk, no reliance on land to scale. 

Chanelle McCoy Health was founded by pharmaceutical trailblazers Lady Chanelle McCoy and Caroline Glynn Sc., MSc., L.LM with 20 years in the pharma industry, registering over 2,500+ much needed medical licenses across 96 countries.

Qualified with a degree in Pharmacology, a Masters in Biomedical Science and a Masters in Law, Founder and CSO, Caroline Glynn B.Sc., MSc., L.LM commented on this pivotal moment for the company: “The beginning of this trial is incredibly significant for Chanelle McCoy Health as a company but also in driving the data surrounding Ultra Pure Synthetic CBD. We are beginning the process of recruiting for our clinical trial. Registering our Product as an OTC medicine will allow us to finally address the demands of many people who suffer from insomnia or sleep disturbance. This is the first of many Phase III Efficacy Clinical Studies in our R&D Strategic Plan using our Ultra Pure Synthetic CBD.”

Both Chanelle and Caroline knew they had the expertise to carry out clinical safety studies and navigate through tricky regulatory landscapes to develop the highest quality CBD. With no Ultra Pure CBD on the market, they embarked on their mission to bring a pure, safe, quality assured CBD product that was backed by clinical studies. Since setting up the company, the pair have taken the UK market by storm having gained years of experience in marketing a Synthetic CBD in various forms as a food supplement on the UK market.

Chanelle McCoy Health had already completed a Phase I Safety and Toxicity Pre-Clinical Trials, various parameters were assessed:

Clinical observationsHaematology (blood analysis)
MobilityClinical chemistry (analysis of bodily fluids)
Reaction sensationOrgan and tissue examination
Body temperatureHistology (microscopic structure of tissues)
Ophthalmology (conditions relating to the eye)Sperm evaluation

Latest news

Tetra Pharm Technologies Secures €9 Million In Series A Round To Expand R&D Operations

PRESS RELEASE THE Scandinavian Biotech company, Tetra Pharm Technologies has secured €9M in a series A round led by a...

European Cannabis Stocks Review: OCT Shares Fall As Co-Founder Divests, Cannabis Poland Secures Funding, & Akanda’s Legal Battle Continues

Oxford Cannabinoid Technologies  THE pharmaceutical cannabis company has seen its shares drop around 25% this week, following weeks of the...

European Round-Up: France’s CESE Calls For End To ‘Bitter Failure’ Of Cannabis Prohibition, Clever Leaves and Tilray Slash Portuguese Operations, & More From Czechia...

FRANCE’s Economic, Social and Environmental Council (CESE) has released a ‘draft opinion’ calling for the legalisation of cannabis.  On Tuesday,...

22nd Century Group (XXII) Acquires RX Pharmatech Ltd, Greatly Strengthening UK And EU Market Position

PRESS RELEASE 22nd Century Group, Inc. (Nasdaq: XXII), a leading biotechnology company dedicated to improving health with reduced nicotine tobacco, hemp/cannabis...

Czechia Could Be A ‘Step Towards Convincing The Rest Of Europe To Create A Legal Cannabis Framework’

EARLIER this week, Czechia’s national anti-drug coordinator Jindřich Vobořil, described as the ‘locomotive’ driving rapid cannabis reform in the...

Hellenic Dynamics ‘On Track’ To Supply Flowers To Germany By Mid 2023

PRESS RELEASE Hellenic Dynamics' core strategy is to develop and operate its 40,000 square metre active THC cultivation licence from...

Must read

You might also likeRELATED
Recommended to you